IRIS: Different Infusion Rates of Magnesium Sulphate Before Preterm Birth for Neuroprotection Trial.
This trial has completed recruitment.
The 2009 Doyle Cochrane systematic review established the neuroprotective role of antenatal magnesium sulphate for the preterm fetus, demonstrating that 63 women would need to be treated to benefit one baby by avoiding cerebral palsy (95% confidence interval 43 to 155). The 2010 Antenatal Magnesium Sulphate Prior to Preterm Birth for Neuroprotection of the Fetus, Infant and Child National Clinical Practice Guidelines, now recommend antenatal magnesium sulphate in women at risk of early preterm (gestational age less than 30 weeks), imminent birth (when early preterm birth is planned or definitely expected within 24 hours). The IRIS trial aims to assess the effect of administering antenatal magnesium sulphate for fetal neuroprotection at a slower loading infusion rate as compared with the current recommended infusion rate on maternal adverse effects.
|Chief Investigators:||Professor Caroline Crowther|
|Clinical Trial Coordinator:||Ms Emily Bain|
|Phone:||61 8 8161 8429|
|Fax:||61 8 8161 7652|
|Collaborating Centres:||Women's and Children's Hospital, Adelaide, South Australia|
- Bain E, Middleton P, Crowther CA. Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth (Protocol). Cochrane Database Syst Rev. 2011(9).
- The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal Magnesium Sulphate Prior to Preterm Birth for Neuroprotection of the Fetus, Infant and Child: National Clinical Practice Guidelines. Adelaide: The University of Adelaide; 2010.
- Doyle LW, Crowther CA, Middleton P, Marret S, Rouse DJ. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews 2009; Issue 1. Art. No.: CD004661. DOI:10.1002/14651858.CD004661.pub3.